Dashboard
Weak Long Term Fundamental Strength with a -17.14% CAGR growth in Operating Profits over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 0.50
- The company has been able to generate a Return on Equity (avg) of 5.17% signifying low profitability per unit of shareholders funds
Negative results in Sep 26
Stock is technically in a Mildly Bearish range
With ROE of 2.4, it has a Very Expensive valuation with a 2.3 Price to Book Value
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
INR 50 Cr (Micro Cap)
96.00
40
0.00%
0.01
2.39%
2.22
Total Returns (Price + Dividend) 
Biofil Chemicals for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Biofil Chemicals & Pharmaceuticals Ltd is Rated Strong Sell
Biofil Chemicals & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 16 September 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 28 October 2026, providing investors with the latest perspective on the company’s position.
Read More
Biofil Chemicals & Pharmaceuticals Ltd is Rated Strong Sell
Biofil Chemicals & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 16 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 October 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Biofil Chemicals & Pharmaceuticals Ltd is Rated Strong Sell
Biofil Chemicals & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 16 September 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 29 September 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Newspaper Publication
16-Nov-2026 | Source : BSESubmission of publication of Un-audited financial results in the Newspaper pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.
To Review Consider And Approve The Standalone Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September 2026 Along With Limited Review Report.
14-Nov-2026 | Source : BSETo review consider and approve the Standalone Unaudited Financial Results for the quarter and half year ended on 30th September 2026 along with limited review report
Board Meeting Outcome for Board Meeting Outcome To Review Consider And Approve The Standalone Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September 2026 Along With Limited Review Report
14-Nov-2026 | Source : BSETo review consider and approve the Standalone Unaudited Financial Results for the quarter and half year ended on 30th September 2026 along with Limited Review Report.
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Non Institution
None
Held by 0 Schemes
Held by 0 FIIs
Scope Finance Company Private Limited (13.9%)
Starline Equifin Private Limited (7.07%)
38.54%
Quarterly Results Snapshot (Standalone) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is -86.48% vs 63.14% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is 9.09% vs -47.62% in Jun 2026
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 83.89% vs -45.15% in Sep 2024
Growth in half year ended Sep 2025 is 1,210.53% vs -48.65% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is -16.88% vs 0.93% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 634.29% vs -23.91% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is -14.97% vs -16.58% in Mar 2025
YoY Growth in year ended Mar 2026 is 398.21% vs -21.13% in Mar 2025